Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Metastatic Pancreatic Cancer
DRUG: FOLFIRINOX treatment
Progression-free survival (PFS), Progression-free survival (PFS) on FOLFIRINOX3 at 6 months., 6 months
Overall survival (OS), Overall survival (OS) is defined as the time interval between the date of inclusion and the date of death from any cause., 24 months|Acute and late toxicities (adverses events), Acute toxicity is defined as toxicity occurring within 6 months of the start of chemotherapy.

A toxicity is late if it occurs more than 6 months after the start of chemotherapy., Until 30 days after the end of treatment|Quality of life (QoL), Quality of life (QoL) will be assessed at inclusion, every 4 courses up to 6 months, then every 8 courses using questionnaires validated by the EORTC (European Organisation for Research and Treatment of Cancer): the cancer-specific QLQ-C30, Until the end of treatment an average of 14 months|Quality of life (QoL), Quality of life (QoL) will be assessed at inclusion, every 4 courses up to 6 months, then every 8 courses using questionnaires validated by the EORTC (European Organisation for Research and Treatment of Cancer): the QLQPAN26,a module specific to pancreatic cancer., Until the end of treatment an average of 14 months
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.

Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses. Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.